Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company whose news flow is centered on its AI Nose SmellTech platform and related AI infrastructure, alongside development of its low-dose oral interferon candidate, VELDONA. Company updates frequently highlight progress in digitizing scent into Smell ID, expanding industrial deployments, and advancing its Smell Language Model (SLM) through its subsidiary ScentAI Inc.
On this page, readers can follow AIMD news related to industrial partnerships, commercialization milestones, and strategic agreements. Recent announcements have covered distribution and deployment partnerships in semiconductor front-end manufacturing, collaborations with industrial computing and edge AI providers, and expansion of AI Nose pilots across smart factories, robotics, and healthcare environments. Ainos also issues press releases on its GICS reclassification into the technology sector, intellectual property additions, and SmellTech-as-a-Service contracts.
Investors and observers can expect news items on topics such as multi-year SmellTech-as-a-Service agreements, pilot deployments in senior care and robotics, new patents for AI Nose and digital olfaction, and updates on the company’s platform strategy to separate sensing hardware (Ainos) from AI intelligence (ScentAI). Financial result releases and associated commentary provide additional context on research and development priorities and commercialization roadmaps.
By monitoring this news feed, users gain a consolidated view of how Ainos is building its SmellTech ecosystem across semiconductors, industrial automation, robotics, and healthcare, while continuing to develop its VELDONA oral interferon program. Bookmark this page for ongoing coverage of AIMD press releases, partnership announcements, and regulatory communications.
Ainos (NASDAQ:AIMD) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company was initially notified on July 15, 2024, that its stock price had been trading below the required $1.00 minimum for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). After the initial 180-day compliance period ending January 13, 2025, Nasdaq has granted Ainos an additional extension until July 14, 2025 to meet the minimum bid requirement.
The company's shares will continue to trade on the Nasdaq Capital Market during this extension period, with no immediate effect on its listing status.
Ainos (NASDAQ:AIMD) has announced its AI Nose technology for robotics applications and launched the Ainos Alliance initiative, inviting global robotics companies to collaborate. The AI Nose technology, developed over nearly a decade, combines AI and MEMS gas sensors to enable robots to detect smells, targeting applications in home safety, healthcare, and industrial environments.
The technology offers capabilities including gas leak detection, disease detection through VOC analysis, and environmental monitoring. This announcement comes amid significant market growth projections, with the global robotics market expected to reach $178.63 billion by 2030, and the electronic nose market projected to hit $65.79 billion by 2031.
Through the Ainos Alliance, robotics companies can access this patented technology to enhance their products' capabilities in industrial safety, healthcare, and smart living applications.
Ainos (NASDAQ:AIMD) has shared its achievements and future plans in a shareholder letter. The company is developing AI Nose technology through Smell ID, achieving 80% accuracy in VOC detection platform with plans for mass production in H1 2025. Their Ainos Flora device for women's health achieved up to 94% accuracy in clinical trials, with second-generation studies planned for H1 2025.
The company's VELDONA low-dose interferon therapy is advancing with clinical trials for Sjögren's Syndrome and HIV-related oral warts scheduled to begin in H1 2025. A strategic partnership with Taiwan Tanabe Seiyaku Co. will support VELDONA's manufacturing and commercialization. The company also plans to complete veterinary trials for feline chronic gingivostomatitis by H1 2025.
Ainos (NASDAQ:AIMD) outlines its achievements and future plans in AI-powered healthcare technology. The company is developing Smell ID, an AI-powered smell detection technology, and advancing VELDONA®, a low-dose interferon therapeutic. Key developments include:
- The Ainos Flora device for STI testing achieved 94% accuracy in clinical trials, with second-generation studies planned for H1 2025
- VOC detection platform reached 80% accuracy through collaborations with Nisshinbo Micro Devices and Itochu Techno-Solutions
- Clinical trials for VELDONA® targeting Sjögren's Syndrome and HIV-related oral warts are set to begin in H1 2025
- Strategic partnership with Taiwan Tanabe Seiyaku for VELDONA® manufacturing and commercialization
Ainos (NASDAQ:AIMD), a healthcare company specializing in AI-driven point-of-care testing and low-dose interferon therapeutics, has announced its participation in the Webull Corporate Connect Service (CCS). This strategic move aims to enhance investor engagement and transparency through real-time communication with shareholders.
Through the CCS platform, Ainos will showcase corporate milestones, strategic initiatives, and financial results to the investment community. The company's Chairman and CEO, Chun-Hsien Tsai, emphasized that this integration aligns with their commitment to transparent investor communication and will help drive long-term shareholder value.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with Taiwan Tanabe Seiyaku, a Mitsubishi Tanabe Pharma subsidiary, for manufacturing and marketing VELDONA® in Taiwan. The partnership focuses on advancing VELDONA®, a therapeutic candidate for primary Sjögren's syndrome.
The collaboration leverages Taiwan Tanabe Seiyaku's PIC/S GMP-certified facility and expertise in drug manufacturing and market promotion. A clinical study of VELDONA® has received Institutional Review Board approval from Shuang Ho Hospital, with site initiation planned for April 2025 and completion expected in December 2026. Previous U.S. Phase 3 studies showed VELDONA® benefits in improving oral dryness and salivary function for Sjögren's syndrome, an autoimmune disease affecting 0.1-1.0% of the global population.
Ainos (NASDAQ: AIMD) has signed a strategic Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma , to advance the manufacturing and Taiwan market promotion of VELDONA®, their Sjögren's syndrome treatment drug. The partnership leverages Taiwan Tanabe Seiyaku's pharmaceutical development and manufacturing expertise. VELDONA®, a low-dose oral interferon-alpha, has shown promising results in clinical trials, demonstrating significant symptom alleviation and disease progression control. The collaboration aims to accelerate VELDONA®'s global market introduction, targeting the growing Sjögren's syndrome market projected to reach billions in the next five years.
Water Tower Research has published a report highlighting Ainos (NASDAQ:AIMD) receiving IRB approval from Shuang Ho Hospital for its VELDONA clinical study in primary Sjogren's syndrome. The trial is expected to begin around April 2025 after TFDA approval, with completion targeted for December 2026. The study will enroll 24 patients over 24-48 weeks to evaluate VELDONA's efficacy in improving salivary flow. Previous U.S. Phase 3 studies showed positive results. The company recently secured exclusive licenses to 28 patent assets for AI Nose VOC sensing, POCT, and other technologies. Ainos maintains sufficient cash to support operations through 2H25.
Ainos (NASDAQ:AIMD) has received IRB approval from Shuang Ho Hospital for its clinical trial of VELDONA® in treating Sjögren's syndrome. The company plans to commence a site initiation visit around April 2025, pending regulatory approvals. The study will recruit 24 patients for a 24- to 48-week treatment period. Previous U.S. clinical trials, including three Phase 3 studies, demonstrated VELDONA® significantly increases unstimulated whole salivary flow. The trial's primary endpoint is to evaluate VELDONA®'s efficacy in improving salivary flow and alleviating dryness symptoms. Patient recruitment will begin in May 2025, with study completion expected by December 2026.
Ainos (NASDAQ: AIMD) has filed complaints with NASDAQ MarketWatch and the SEC regarding suspicious trading activities in its common stock, particularly concerning large-volume sell orders. The healthcare company, which specializes in AI-powered point-of-care testing and interferon therapeutics, suspects potential regulatory violations and has requested thorough investigation to protect stockholder interests. While regulatory bodies won't confirm any investigation details, Ainos maintains its commitment to market transparency and investor protection.